BioNTech and Pfizer Agree to $1.2 Billion Settlement Over U.S. Vaccine Patent Disputes

The payments resolve licensing disagreements with the NIH and the University of Pennsylvania without admitting liability.

BioNTech and Pfizer will pay a combined $1.2 billion to settle disputes over Covid-19 vaccine patent rights in the U.S.
Approximately $759 million will go to the National Institutes of Health (NIH), with Pfizer contributing $350 million of that amount.
The University of Pennsylvania will receive up to $448 million, with Pfizer covering $163 million of this payment.
The disputes involved non-exclusive rights to patent applications used in the development of the companies' Covid-19 vaccine.
BioNTech emphasized that these settlements do not constitute an admission of liability and differ from ongoing legal battles with competitors like Moderna and CureVac.